[Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Zhou
Ting
T
Institute of Pharmacology and Toxicology, Academy of Military Medical Science, Beijing 100850, China.
Xie
Lan
L
D000480:Alkynes; D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D048588:Benzoxazines; D003374:Coumarins / Q000737:chemistry / Q000494:pharmacology; D003521:Cyclopropanes; D020008:Delavirdine / Q000737:chemistry / Q000494:pharmacology; D024882:Drug Resistance, Viral; D054303:HIV Reverse Transcriptase / Q000187:drug effects*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008968:Molecular Conformation; D015394:Molecular Structure; D019829:Nevirapine / Q000737:chemistry / Q000494:pharmacology; D010078:Oxazines / Q000737:chemistry / Q000494:pharmacology; D039681:Pyranocoumarins; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003374:Coumarins; D003521:Cyclopropanes; D010078:Oxazines; D039681:Pyranocoumarins; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D020008:Delavirdine; D054303:HIV Reverse Transcriptase; C098320:efavirenz; C075959:calanolide A